ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions - PubMed (original) (raw)
. 2006 Apr 1;66(7):3715-25.
doi: 10.1158/0008-5472.CAN-05-2823.
Ekkehart U Lausch, Tatjana M Trost, Dirk Prawitt, Andreas May, Romy Keppler, Stephan A Fees, Dirk Reutzel, Carolin Bell, Steffen Schmitt, Ilka B Schiffer, Achim Weber, Walburgis Brenner, Matthias Hermes, Ugur Sahin, Ozlem Türeci, Heinz Koelbl, Jan G Hengstler, Bernhard U Zabel
Affiliations
- PMID: 16585198
- DOI: 10.1158/0008-5472.CAN-05-2823
ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions
Christian Spangenberg et al. Cancer Res. 2006.
Abstract
Oncogenic activation of the receptor tyrosine kinase ERBB2 is a key event in the development of a number of epithelial malignancies. In these tumors, high levels of ERBB2 are strongly associated with metastatic disease and poor prognosis. Paradoxically, an inherent cellular response to hypermitogenic signaling by ERBB2 and other oncogenes seems to be growth arrest, rather than proliferation. Molecular characterization of this yet undefined antiproliferative state in independent cell lines overexpressing either wild-type ERBB2 or the mutationally activated receptor unveiled a dramatic induction of the alpha5beta1 integrin fibronectin receptor. alpha5 Integrin up-regulation is mainly a transcriptional response mediated by the hypoxia-inducible transcription factors (HIF), leading to a massive increase in membrane-resident receptor molecules and enhanced fibronectin adhesiveness of the respective cells. Functionally, ERBB2-dependent ligation of fibronectin results in improved survival of mammary adenocarcinoma cells under adverse conditions, like serum withdrawal, hypoxia, and chemotherapy. HIF-1alpha is an independent predictor of poor overall survival in patients with breast cancer. In particular, HIF-1alpha overexpression correlates significantly with early local relapse and distant metastasis, a phenotype also highly characteristic of ERBB2-positive tumors. As HIF-1alpha is known to be stabilized by ERBB2 signaling under normoxic conditions, we propose that alpha5 integrin is a major effector in this regulatory circuit and may represent the molecular basis for the HIF-1alpha-dependent aggressiveness observed in ERBB2-overexpressing breast carcinomas. Hypermitogenic ERBB2 signaling and tumor hypoxia may act synergistically to favor the establishment of chemoresistant dormant micrometastatic cells frequently observed in patients with breast cancer. This new insight could be the basis for additional approaches complementing current cancer therapy.
Similar articles
- Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.
Trost TM, Lausch EU, Fees SA, Schmitt S, Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer IB, Heimerdinger CK, Hengstler JG, Fritz G, Bockamp EO, Prawitt D, Zabel BU, Spangenberg C. Trost TM, et al. Cancer Res. 2005 Feb 1;65(3):840-9. Cancer Res. 2005. PMID: 15705882 - Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL. Xia W, et al. Cancer Res. 2006 Feb 1;66(3):1640-7. doi: 10.1158/0008-5472.CAN-05-2000. Cancer Res. 2006. PMID: 16452223 - A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.
Hua G, Zhu B, Rosa F, Deblon N, Adélaïde J, Kahn-Perlès B, Birnbaum D, Imbert J. Hua G, et al. Mol Cancer Res. 2009 Mar;7(3):402-14. doi: 10.1158/1541-7786.MCR-08-0175. Epub 2009 Mar 10. Mol Cancer Res. 2009. PMID: 19276186 - Hypoxia-inducible factor-1 in human breast and prostate cancer.
Kimbro KS, Simons JW. Kimbro KS, et al. Endocr Relat Cancer. 2006 Sep;13(3):739-49. doi: 10.1677/erc.1.00728. Endocr Relat Cancer. 2006. PMID: 16954428 Review. - Co-opted integrin signaling in ErbB2-induced mammary tumor progression.
Carraway KL 3rd, Sweeney C. Carraway KL 3rd, et al. Cancer Cell. 2006 Aug;10(2):93-5. doi: 10.1016/j.ccr.2006.07.015. Cancer Cell. 2006. PMID: 16904607 Review.
Cited by
- Viscoelasticity, Like Forces, Plays a Role in Mechanotransduction.
Mierke CT. Mierke CT. Front Cell Dev Biol. 2022 Feb 9;10:789841. doi: 10.3389/fcell.2022.789841. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35223831 Free PMC article. Review. - Integrins as attractive targets for cancer therapeutics.
Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Li M, et al. Acta Pharm Sin B. 2021 Sep;11(9):2726-2737. doi: 10.1016/j.apsb.2021.01.004. Epub 2021 Apr 10. Acta Pharm Sin B. 2021. PMID: 34589393 Free PMC article. Review. - Cancer Immunoprevention: Current Status and Future Directions.
Keshavarz-Fathi M, Rezaei N. Keshavarz-Fathi M, et al. Arch Immunol Ther Exp (Warsz). 2021 Feb 27;69(1):3. doi: 10.1007/s00005-021-00604-x. Arch Immunol Ther Exp (Warsz). 2021. PMID: 33638703 Review. - Biomarkers to quantify cell migration characteristics.
Kwon S, Yang W, Moon D, Kim KS. Kwon S, et al. Cancer Cell Int. 2020 Jun 5;20:217. doi: 10.1186/s12935-020-01312-w. eCollection 2020. Cancer Cell Int. 2020. PMID: 32518526 Free PMC article. - LIPG supports adaption to oxidative stress.
Leonhardt G. Leonhardt G. EXCLI J. 2019 Jul 10;18:499-500. doi: 10.17179/excli2019-1555. eCollection 2019. EXCLI J. 2019. PMID: 31423129 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous